GENELUX CORPORATION
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.genelux.com
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer RecurrentMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT06463665
- Locations
- ๐บ๐ธ
Michigan Hematology and Oncology Consultants, Dearborn, Michigan, United States
๐บ๐ธOakland Medical Group, Farmington Hills, Michigan, United States
๐บ๐ธTexas Oncology - Austin Central, Austin, Texas, United States
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05281471
- Locations
- ๐บ๐ธ
Sarasota Memorial Research Institute, Sarasota, Florida, United States
๐บ๐ธUniversity of Texas Science Center at Houston, McGovern Medical School, Houston, Texas, United States
๐บ๐ธThe University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Genelux Corporation
- Registration Number
- NCT03420430
- Locations
- ๐บ๐ธ
Florida Hospital Cancer Institute, Orlando, Florida, United States
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT02759588
- Locations
- ๐บ๐ธ
Gynecologic Oncology Associates, Newport Beach, California, United States
๐บ๐ธAdventHealth Cancer Institute, Orlando, Florida, United States
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
- Conditions
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 19
- Registration Number
- NCT01584284
- Locations
- ๐บ๐ธ
Moores UC San Diego Cancer Center, La Jolla, California, United States
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 43
- Registration Number
- NCT00794131
- Locations
- ๐ฌ๐ง
Royal Marsden Hospital, Surrey, United Kingdom